Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025OncoTargets and TherapyOpen Access

Immune-Checkpoint Inhibitors in Lung Neuroendocrine Tumors – A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

RPRita Carrilho PichelLBLavinia BeniniMRMarco Romelli

Discussion

Loading...

Member takes

Overview

Systematic review highlights the overall response rate for immune-checkpoint inhibitors in lung NETs, indicating potential for improved treatment options.

Key Points

  • The analysis found an overall response rate of 14.7% among patients with lung neuroendocrine tumors, indicating some effectiveness of immune-checkpoint inhibitors.
  • Subgroup analysis revealed a higher overall response rate of 44.4% for atypical carcinoids among 128 patients included in the meta-analysis.
  • This systematic review evaluated 11 studies, primarily Phase II trials, assessing the efficacy of immune-checkpoint inhibitors and their combination treatments.
  • The findings suggest potential benefits of immune-checkpoint inhibitors in treating lung neuroendocrine tumors, especially atypical carcinoids, but further research is warranted.

Cite This Study

Pichel et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d647902fchttps://doi.org/10.2147/ott.s515194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An update on the role of immune checkpoint inhibitors in lung cancer: A narrative systematic review2025
  2. 2Alteration of Prognostic Factors for Patients with Brain Metastases from Lung Cancer Before and After the Introduction of Immune Checkpoint Inhibitors: A Retrospective Single-Institution Study2025
  3. 3Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis2025
  4. 4Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis2025 · 2 citations
  5. 5The Utility of Immune Checkpoint Inhibition in the Management of Resectable Non-Small Cell Lung Cancer2025